Vantage logo

Biotech catalysts on the horizon

The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.

Vantage logo

Coral wrecks Sage

Approval for zuranolone might be in reach, but meeting sales expectations could be a different story.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.